C.J. Twelves
Cancer Research Campaign Department of Medical Oncology
University of Glasgow
and Beatson Oncology Centre
Glasgow
United Kingdom
Name/email consistency: high
- Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Twelves, C. Eur. J. Cancer (2002)
- Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Twelves, C., Campone, M., Coudert, B., Van den Bent, M., de Jonge, M., Dittrich, C., Rampling, R., Sorio, R., Lacombe, D., de Balincourt, C., Fumoleau, P. Ann. Oncol. (2002)
- Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?. Twelves, C.J., Cassidy, J. Br. J. Cancer (2002)
- Vision of the future: capecitabine. Twelves, C. Oncologist (2001)